FDA panel recommends change to label of Bristol-Myers' Abilify

12/9/2009 | Reuters

An FDA panel unanimously concluded that the label of Bristol-Myers Squibb's antipsychotic Abilify for use in children lacks information on the risk of excessive weight gain. The panel advised Bristol-Myers to keep monitoring pediatric use of the drug and move data on its metabolic effect on children to the warning section of the label.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA